Compare EFSI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EFSI | CCCC |
|---|---|---|
| Founded | 1881 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.3M | 240.3M |
| IPO Year | N/A | 2020 |
| Metric | EFSI | CCCC |
|---|---|---|
| Price | $40.05 | $2.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $39.50 | $7.25 |
| AVG Volume (30 Days) | 15.1K | ★ 1.5M |
| Earning Date | 10-23-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.13 | N/A |
| Revenue | ★ $66,122,000.00 | $30,108,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.28 | N/A |
| P/E Ratio | $18.83 | ★ N/A |
| Revenue Growth | ★ 3.18 | N/A |
| 52 Week Low | $28.70 | $1.09 |
| 52 Week High | $40.71 | $4.44 |
| Indicator | EFSI | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 77.71 | 34.55 |
| Support Level | $39.51 | $2.50 |
| Resistance Level | $40.71 | $2.69 |
| Average True Range (ATR) | 0.78 | 0.19 |
| MACD | 0.25 | -0.07 |
| Stochastic Oscillator | 98.36 | 5.92 |
Eagle Financial Services Inc is a locally owned and managed financial institution. It offers retail and commercial banking services, including demand, savings and time deposits and consumer, mortgage, and commercial loans. It also offers telephone banking, internet banking, and mobile banking to its customers. The Company has three reportable operating segments, Community Banking, Marine Lending and Wealth Management. It generates a majority of its revenue from the Community Banking segment.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.